{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:18:15Z","timestamp":1757618295971,"version":"3.44.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40744-025-00771-9","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:40:34Z","timestamp":1748774434000},"page":"663-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks"],"prefix":"10.1007","volume":"12","author":[{"given":"Suzy","family":"van Sanden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barkha P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-9782","authenticated-orcid":false,"given":"Fareen","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"issue":"10","key":"771_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103410","volume":"22","author":"G Monteleone","year":"2023","unstructured":"Monteleone G, Moscardelli A, Colella A, Marafini I, Salvatori S. Immune-mediated inflammatory diseases: common and different pathogenic and clinical features. Autoimmun Rev. 2023;22(10): 103410.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"771_CR2","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40744-021-00365-1","volume":"8","author":"W Saalfeld","year":"2021","unstructured":"Saalfeld W, Mixon AM, Zelie J, Lydon EJ. Differentiating psoriatic arthritis from osteoarthritis and rheumatoid arthritis: a narrative review and guide for advanced practice providers. Rheumatol Ther. 2021;8(4):1493\u2013517.","journal-title":"Rheumatol Ther"},{"key":"771_CR3","doi-asserted-by":"publisher","first-page":"175972022108671","DOI":"10.1177\/1759720X221086710","volume":"14","author":"S Hackett","year":"2022","unstructured":"Hackett S, Ogdie A, Coates LC. Psoriatic arthritis: prospects for the future. Ther Adv Musculoskelet Dis. 2022;14:1759720221086710.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"7","key":"771_CR4","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1093\/rheumatology\/keab329","volume":"60","author":"H Marzo-Ortega","year":"2021","unstructured":"Marzo-Ortega H, Packham J, Pujades-Rodriguez M. \u201cToo much of a good thing\u201d: can network meta-analysis guide treatment decision-making in psoriatic arthritis? Rheumatology (Oxford). 2021;60(7):3042\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"771_CR5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/rheumatology\/keac500","volume":"62","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2023;62(4):1417\u201325.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"771_CR6","doi-asserted-by":"publisher","first-page":"e002074","DOI":"10.1136\/rmdopen-2021-002074","volume":"8","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C, Helliwell PS. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open. 2022;8(1):e002074.","journal-title":"RMD Open"},{"issue":"2","key":"771_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2018;38(2):200\u201311.","journal-title":"Med Decis Mak"},{"issue":"6","key":"771_CR8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"5","key":"771_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33(5):607\u201317.","journal-title":"Med Decis Mak"},{"issue":"6","key":"771_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"771_CR11","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. (Technical Support Documents). NICE Decision Support Unit. 2016. https:\/\/research-information.bris.ac.uk\/files\/94868463\/Population_adjustment_TSD_FINAL.pdf."},{"issue":"1","key":"771_CR12","doi-asserted-by":"publisher","first-page":"2169574","DOI":"10.1080\/09546634.2023.2169574","volume":"34","author":"J Signorovitch","year":"2023","unstructured":"Signorovitch J, Diels J, Van Sanden S, et al. Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis. J Dermatol Treat. 2023;34(1):2169574.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"771_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","volume":"20","author":"P Nash","year":"2018","unstructured":"Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"771_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landewe R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9999","key":"771_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"3","key":"771_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","volume":"6","author":"AJ Kivitz","year":"2019","unstructured":"Kivitz AJ, Nash P, Tahir H, et al. Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study. Rheumatol Ther. 2019;6(3):393\u2013407.","journal-title":"Rheumatol Ther"},{"issue":"14","key":"771_CR17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"10230","key":"771_CR18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"issue":"10230","key":"771_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"3","key":"771_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359\u201369.","journal-title":"Ann Rheum Dis"},{"issue":"10235","key":"771_CR21","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496\u2013505.","journal-title":"Lancet"},{"key":"771_CR22","unstructured":"TREMFYA. European Medicines Agency Summary of Product Characteristics [updated July 22, 2022]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tremfya-epar-product-information_en.pdf."},{"key":"771_CR23","unstructured":"COSENTYX. European Medicines Agency Summary of Product Characteristics [updated August 30, 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf."},{"issue":"3","key":"771_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475\u201385.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"771_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604\u201316.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"771_CR26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3899\/jrheum.160275","volume":"43","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, McInnes IB, Mease PJ, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol. 2016;43(9):1713\u20137.","journal-title":"J Rheumatol"},{"issue":"11","key":"771_CR27","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","volume":"56","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56(11):1993\u20132003.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"771_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13075-018-1610-3","volume":"20","author":"IB McInnes","year":"2018","unstructured":"McInnes IB, Mease PJ, Schett G, et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res Ther. 2018;20(1):113.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"771_CR29","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","volume":"2","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Mease PJ, Kivitz AJ, et al. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatol. 2020;2(4):e227\u201335.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"771_CR30","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","volume":"59","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde D, Mease PJ, Landewe RBM, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford). 2020;59(6):1325\u201334.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"771_CR31","doi-asserted-by":"publisher","first-page":"e001600","DOI":"10.1136\/rmdopen-2021-001600","volume":"7","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Landewe R, Rahman P, et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 2021;7(2):e001600.","journal-title":"RMD Open"},{"issue":"5","key":"771_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"771_CR33","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1093\/rheumatology\/keac295","volume":"61","author":"L Tucker","year":"2022","unstructured":"Tucker L, Allen A, Chandler D, et al. The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology (Oxford). 2022;61(9):e255\u201366.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"771_CR34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"key":"771_CR35","first-page":"65","volume":"97","author":"LC Coates","year":"2021","unstructured":"Coates LC, Corp N, van der Windt DA, Soriano ER, Kavanaugh A. GRAPPA treatment recommendations: an update from the 2020 GRAPPA annual meeting. J Rheumatol Suppl. 2021;97:65\u20136.","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"771_CR36","doi-asserted-by":"publisher","first-page":"e002195","DOI":"10.1136\/rmdopen-2022-002195","volume":"8","author":"CT Ritchlin","year":"2022","unstructured":"Ritchlin CT, Mease PJ, Boehncke WH, et al. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open. 2022;8(1):e002195.","journal-title":"RMD Open"},{"issue":"1","key":"771_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"key":"771_CR38","unstructured":"UCB. UCB announces a head-to-head study evaluating BIMZELX\u00ae (bimekizumab) versus SKYRIZI\u00ae (risankizumab) in active psoriatic arthritis. [updated 2024, September 30]. Available from: https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/ucb-announces-a-head-to-head-study-evaluating-bimzelxrvbimekizumab-versus-skyrizir-risankizumab-in-active-psoriatic-arthritis."},{"key":"771_CR39","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jval.2020.04.013","volume":"23","author":"T Disher","year":"2020","unstructured":"Disher T, Peterson S, Eaton K, et al. CE1 Methodological challenges with conducting Network Meta-analyses assessing long-term comparative efficacy in psoriasis: a critique of assumptions underpinning recent indirect treatment comparisons. Value Health. 2020;23:S2\u20133.","journal-title":"Value Health"},{"issue":"2","key":"771_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40744-022-00518-w","volume":"10","author":"S Siebert","year":"2023","unstructured":"Doura, K., Mel\u00e9ndez-Morales, J. D., Meyer, G. G., & P\u00e9rez, L. E. (1999). An S\u2013I\u2013S model of streptococcal disease with a class of beta-hemolytic carriers (Technical Report No. BU-1524-M). Cornell University, Biometrics Unit.","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00771-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00771-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00771-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:16:36Z","timestamp":1757178996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00771-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00771-9","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2025,6,1]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Suzy van Sanden, Agata Schubert, Miriam Zimmermann, and Fareen Hassan are employees of Johnson & Johnson Innovative Medicine. Barkha P. Patel is an employee of EVERSANA, which received funding from Johnson & Johnson Innovative Medicine for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}